SynthesisGlobal health action2021
Demographic, regional and temporal trends of hyperuricemia epidemics in mainland China from 2000 to 2019: a systematic review and meta-analysis.
Synthesis in Global health action, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Gout, hyperuricemia, and male reproductive health: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- A systematic review and meta-analysis of the hyperuricemia risk from certain metals.Clinical rheumatology · 2022Pooled it
- Development and Internal Validation of a Risk Prediction Model for Carotid Atherosclerosis in the Hyperuricemia Population.Vascular health and risk management · 2024Trial
- Phragmites Communis (Lu Gen) Alleviates Hyperuricemia via Xanthine Oxidase Inhibition and Gut-Microbiota-Mediated Metabolite Urate Transporter Regulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Factors associated with hyperuricemia in overweight or obese adults of Shenzhen, China.Scientific reports · 2026Article
- Potent and Sustained Lowering of Serum Uric Acid by YJH-012-D, a GalNAc-Conjugated siRNA Targeting Xanthine Dehydrogenase.Pharmacology research & perspectives · 2026Article
- A machine learning approach to metabolomics identifies putative biomarker candidates and dysregulated pathways for distinguishing gout from asymptomatic hyperuricemia in the Zhuang population.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Allopurinol has no effect on calcitriol or other CKD-MBD biomarkers: a randomized double-blind study.Journal of the Endocrine Society · 2026Article
- Article
- Interaction and Joint Effects of Inflammation and Triglyceride-Glucose (TyG) Index on Hyperuricemia Risk and the Mediating Role of TyG: A Cross-Sectional Study.Endocrinology, diabetes & metabolism · 2026Article
- The joint associations of TyG index and hsCRP with hyperuricemia among Chinese adults: a cross-sectional study.Clinical rheumatology · 2026Article
- Serum uric acid levels among children and adolescents in China: percentile reference values and national prevalence estimates of hyperuricemia.BMC medicine · 2026Article
- Preparation and Identification of Corn-Derived Bioactive Peptides with Triple Efficacy of ADH-Activating, XOD-Inhibiting and Antioxidant Activity.Foods (Basel, Switzerland) · 2026Article
- Correlation analysis between the prevalence of hyperuricemia and the triglyceride-glucose index in adult patients with brucellosis.BMC infectious diseases · 2026Article
- Network Pharmacology-Based Exploration: Non-Targeted Metabolites ofBiologics : targets & therapy · 2026Article
- Utility of large language models as information tools for nursing care in gout: a comparative study of DeepSeek and ChatGPT.Frontiers in medicine · 2026Article
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
- Lipoprotein combined index and prevalent hyperuricemia among normolipidemic oilfield workers: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Study on the correlation between hyperuricemia and components of metabolic syndrome in T2DM in China: a single-center, observational study.Frontiers in endocrinology · 2026Observational
- Association between hyperuricemia and kidney stones in Southern China: a multicentre cross-sectional study.Frontiers in endocrinology · 2026Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia (HUA) is becoming a global public health problem and associated with multiple diseases.
objectiveWe conducted a systematic review to synthesize the pooled prevalence of HUA in mainland China and delineate its demographic, regional, and temporal trends over the past two decades.
methodsSystematic literature searches of PubMed, SCOPUS, Web of Science, the China National Knowledge Infrastructure (CNKI), and the Wanfang digital database were conducted to screen studies published from 1 January 2000 to 31 August 2019, reporting the prevalence of HUA in mainland China. The search strings were ('hyperuricemia' OR 'hyperuricaemia' OR 'uric acid') AND ('prevalence' OR 'epidemiology') AND 'China'. Article quality was appraised quantitatively from 11 items. Before formal meta-analysis, age-standardized prevalence was transformed. The random-effects model was applied to synthesize the pooled prevalence due to its high heterogeneity. Then we stratified the prevalence estimates by age, gender, area, nationality, and publication year for subgroup analysis.
resultsTotally 177 eligible studies with a whole population of 2,277,712 were included in the present meta-analysis. The pooled prevalence in mainland China was estimated at 16.4% (95% CI: 15.3%~17.6%). In studies with the onset age at 20 ~ 29 years old, males had a twice times higher HUA prevalence than females (21.5% vs. 8.9%). The prevalence of HUA was 13.7% (11.8%~15.7%) in people aged 15~ years old, 16.5% in 30~ (14.8%~18.4%), 17.9% in 40~ (16.4%~19.5%), 19.4% in 50~ (17.8%~21.0%), 20.5% in 60~ (18.8%~22.3%), and 24.9% in over 70 (22.9%~27.1%). Stratified by regions, southern (25.5%) and southwestern (21.2%) China shared the highest prevalence, and the lowest prevalence was observed in the northwest (12.6%). From 2001 to 2017, the prevalence estimates of HUA steadily climbed from 8.5% to 18.4% with minor fluctuations. Multiple regression revealed that HUA prevalence was positively correlated to the larger sample size, area, advanced onset age, and published year.
conclusionsThe last two decades witnessed the rapid growth prevalence of HUA in China. Early screening and personalized health education for HUA need to be given enough attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.